Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014.

The call can be accessed by dialing (855) 465-0180 (U.S. and Canada) or (484) 756-4313 (international), and entering passcode 98326456.

To access a live audio webcast of the presentation, please visit the “Investors” section at trevenainc.com. Following the conclusion of the presentation, the webcast will be archived and available for replay on the company's website for 30 days. A replay of the call will be available for 30 days and can be accessed by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), and entering passcode 98326456.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (Preclinical).

Investor Contacts
Trevena, Inc.
Jonathan Violin, 610-354-8840 x231
Director, Investor Relations
jviolin@trevenainc.com
or
Argot Partners
Andrea Rabney, 212-600-1902
President and Chief Executive Officer
andrea@argotpartners.com
or
Media Contact
Argot Partners, 917-763-8106
Eliza Schleifstein
eliza@argotpartners.com

Source: Trevena, Inc.

Released March 11, 2015